ArticleEuropean journal of immunology2007
HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses.
Article in European journal of immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 102 citations in OpenAlex.
- MSCs delivering LIGHT prime immune response against CAFs to harness antigen loss variants.Cancer gene therapy · 2026Article
- Targeting Bcl-xL to eliminate chemotherapy-induced tumor dormancy and prevent breast cancer metastasis.British journal of cancer · 2026Article
- SpottedPy quantifies relationships between spatial transcriptomic hotspots and uncovers environmental cues of epithelial-mesenchymal plasticity in breast cancer.Genome biology · 2024Article
- NOP16 promotes hepatocellular carcinoma progression and triggers EMT through the Keap1-Nrf2 signaling pathway.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024Article
- Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression.Oncogenesis · 2021Article
- Dynamic EMT: a multi-tool for tumor progression.The EMBO journal · 2021Review
- The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response.NPJ precision oncology · 2021Article
- Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens.Communications biology · 2021Article
- The tumor-promoting effects of the adaptive immune system: a cause of hyperprogressive disease in cancer?Cellular and molecular life sciences : CMLS · 2021Review
- Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets.Breast cancer research : BCR · 2020Article
- TGF-β regulates Sca-1 expression and plasticity of pre-neoplastic mammary epithelial stem cells.Scientific reports · 2020Article
- Transgenic T-cell receptor immunotherapy for cancer: building on clinical success.Therapeutic advances in vaccines and immunotherapy · 2020Review
- Cancer immunoediting and resistance to T cell-based immunotherapy.Nature reviews. Clinical oncology · 2019Review
- New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer.Nature reviews. Molecular cell biology · 2019Review
- NK Cell-Based Immunotherapy in Cancer Metastasis.Cancers · 2018Review
- Gr1Journal of leukocyte biology · 2018Article
- Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.Breast cancer research : BCR · 2018Article
- Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy.Oncotarget · 2018Article
- IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression.Journal of leukocyte biology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Induction of tumor-specific immune responses results in the inhibition of tumor development. However, tumors recur because of the tumor immunoediting process that facilitates development of escape mechanisms in tumors. It is not known whether tumor escape is an active process whereby anti-tumor immune responses induce loss or downregulation of the target antigen in the antigen-positive clones. To address this question, we used rat neu-overexpressing mouse mammary carcinoma (MMC) and its relapsed neu antigen-negative variant (ANV). ANV emerged from MMC under pressure from neu-specific T cell responses in vivo. We then cloned residual neu antigen-negative cells from MMC and residual neu antigen-positive cells from ANV. We found marked differences between these neu-negative clones and ANV, demonstrating that the residual neu-negative clones are probably not the origin of ANV. Since initial rejection of MMC was associated with the presence of IFN-gamma-secreting T cells, we treated MMC with IFN-gamma and showed that IFN-gamma could induce downregulation of neu expression in MMC. This appears to be due to methylation of the neu promoter. Together, these data suggest that neu antigen loss is an active process that occurs in primary tumors due to the neu-targeted anti-tumor immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.